Dyadic International, Inc.(DYAI)Earnings, Financials & Key RatiosDyadic International, Inc. (DYAI) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
combined with a negative equity position of -$407.7K, suggests that the current business model faces severe liquidity constraints.
Dyadic International, Inc. (DYAI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Dyadic International, Inc. (DYAI) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.05vs $0.04-25.0% | $1Mvs $903,750+22.9% |
| Q2 2026 | Mar 25, 2026 | $0.06vs $0.03-100.0% | $564,345vs $1M-58.0% |
| Q4 2025 | Nov 12, 2025 | $0.06vs $0.04-50.0% | $1Mvs $1M-13.3% |
| Q3 2025 | Aug 13, 2025 | $0.06vs $0.06+0.0% | $463,449vs $2M-69.1% |
Recent stock market news and headlines for Dyadic International, Inc. (DYAI)
Global Collaborations Continue to Validate Dyadic's C1 Platform and Expand Commercial Opportunity Dyadic's Ebola preparedness work highlights C1's potentia
JUPITER, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on the development and commercialization of scalable microbial protein production platforms for use across life sciences, food, nutrition, industrial, and biopharmaceutical sectors, today announced that the Japan Patent Office has allowed claims covering its proprietary Thermothelomyces heterothallica recombinant protein expression technology.
SmallCaps Daily Sits Down with Joe Hazelton to Discuss Dyadic's Product Strategy, Strategic Partnerships, and Long-Term Growth Vision New York, New York--(Newsfile Corp. - June 22, 2026) - Dyadic Applied BioSolutions, Inc. (NASDAQ: DYAI) ("Dyadic" or the "Company") is entering the next phase of its growth strategy as it expands commercialization efforts across Life Sciences, Food & Nutrition, and Bio-industrial markets. SmallCaps Daily sat down with President and Chief Operating Officer Joe Hazelton to discuss the Company's product portfolio, strategic partnerships, and growing opportunities in non-animal proteins.
Key metrics vs top competitors for Dyadic International, Inc. (DYAI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.06 | $38.63M | -4.61 | -64.74% | -597.63% | -397.8% | — | |
| $2.60 | $236.33M | -5.20 | 18.61% | -40.96% | -68.09% | — | |
| $1.46 | $355.38M | -10.43 | 849.33% | -19.38% | -7.19% | — | |
| $91.03 | $5.67B | -70.02 | 20.32% | -19.85% | -17.46% | — | |
| $2.22 | $122.06M | -1.73 | 15.57% | -468.74% | -26.58% | — | |
| $37.92 | $3.9B | -46.81 | 120.01% | -49.17% | -5.89% | — |
Dyadic International, Inc. (DYAI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Dyadic International, Inc. (DYAI) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 13, 2026·SEC
Mar 30, 2026·SEC
Mar 25, 2026·SEC
Get notified when DYAI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Dyadic International, Inc. (DYAI) stock FAQ — growth, dividends, profitability & financials explained
Dyadic International, Inc. (DYAI) reported $3.0M in revenue for fiscal year 2025. This represents a 1308% increase from $0.2M in 2003.
Dyadic International, Inc. (DYAI) saw revenue decline by 64.7% over the past year.
Dyadic International, Inc. (DYAI) reported a net loss of $7.3M for fiscal year 2025.
Dyadic International, Inc. (DYAI) has a return on equity (ROE) of -397.8%. Negative ROE indicates the company is unprofitable.
Dyadic International, Inc. (DYAI) had negative free cash flow of $5.7M in fiscal year 2025, likely due to heavy capital investments.
